

Press release
Kista, April 11, 2022

CEO Anders Weilandt presents Chordate Medical at Aktiedagen on May 2nd

On Monday 2 May, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the [United States](#), the upcoming representative office in [Saudi Arabia](#) and the marketing efforts in the [United Kingdom](#).

“It is important for us to meet both existing and potential new shareholders. We want to take every opportunity to inform the market and Aktiespararna is an important platform with professional events. They know how to guide their members to good companies and good investments, and it will be extra fun to have a live audience again,” says Anders Weilandt, Chordate CEO.

Aktiedagen is a hybrid event that is held for an audience on Operaterassen and livestreamed on [Aktiespararna's Youtube channel](#) and on <http://www.aktiespararna.se/tv/live>. The event is open to everyone and does not require membership in Aktiespararna. No registration is required to follow the event digitally.

Read more about the event and register for the physical event here: <https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-6>

For more information, please contact:

Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com/en/

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.